RBCC: iPads, iPhones and Other Mobile Devices Inspire New Biotech Applications

RBCC: iPads, iPhones and Other Mobile Devices Inspire New Biotech Applications

Rainbow Coral Corp.Patrick Brown, 813-367-9511President and CEO

As the breakthrough technologies bundled into the Apple (NASDAQ: AAPL) iPhone and iPad inspire new innovations across many different fields of scientific research, emerging biotechnology company Rainbow BioSciences, a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is targeting new mobile biotech applications for commercialization.

“The cutting-edge mobile devices produced by Apple and other developers contains a mix of technologies that researchers are finding invaluable,” said RBCC CEO Patrick Brown. “The cameras, processing power, connectivity and mobility of today’s tablets and smartphones make them ideal tools in the laboratory. Today, experiments can be monitored, recorded, processed and transmitted anywhere in the world with the telephone in your pocket.”

In order to capitalize on the rapid adoption of these new technologies in the biotechnology sector, RBCC is conducting a comprehensive search to find promising new hardware and software applications for the iPad and other devices that can be commercialized successfully. The company is seeking out early-stage developers for potential acquisition and joint venture.

RBCC is exploring many areas of opportunity in the growing biotechnology market. The company is currently negotiating a possible deal to provide funding and expertise toward the development of exciting new projects by emerging biotech innovator Amarantus BioSciences (OTCBB: AMBS). Among other properties, Amarantus owns the rights to a potential cure for Parkinson’s—a promising therapeutic protein known as MANF.

For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit .

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Elan Corp. (NYSE: ELN).

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at []. For investment information and performance data on the company, please visit .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.